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Abstract
Background: Dietary sources of calcium and vitamin D are recommended as a first-line strategy in prevention of
osteoporosis-related fractures but their public health and economic impact has never been studied.
Methods: We designed a population-based model to forecast the potential health outcomes and medical effectiveness
of the daily administration of dairy supplements containing 800 IU of vitamin D and 1 g of calcium in cohorts of subjects,
from both genders, aged 50, 60, 70 and 80 years. Annual costs of dairy products were tested at €150, €250 and €350.
Results: In total, the daily intake of vitamin-D rich dairy products reduces by 30,376 and 16,105 events the number of
osteoporotic fractures in women and men respectively and permits to gain 6605 and 6144 life-years, in women and
men respectively. This intervention is cost-effective from 70 years on in the general population and from 60 years on in
patients at increased risk of osteoporotic fractures.
Conclusion: The recommendation to use dairy products as the preferred source of calcium and vitamin D in aging
males and females is supported by public health and health economic analyses.
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Background
Osteoporosis (OP) is defined as a systemic disease char-
acterized by low bone mass and microarchitectural de-
terioration of bone tissue, with a consequent increase in
bone fragility and susceptibility to fractures (Fx) [1, 2].
Collectively, all OP Fx account for 2.7 million Fx in men
and women in Europe [2]. In 2010, the direct costs of
OP Fx in the five largest EU countries was evaluated at
€29 billion and at €38.7 billion in the 27 countries [3, 4].
All OP Fx but forearm are associated with increased
mortality [5, 6]. In 2012, the number of deaths causally
related to OP Fx in the European union, was estimated
at 43,000 [4], of which 50 % were due to hip Fx, 28 % to
clinical vertebral and 22 % to other Fx [2]. This high
societal and personal burden poses challenges to public
health and physicians [2]. There is a high prevalence of
vitamin D insufficiency in the elderly and dietary
calcium is low in many postmenopausal OP women
[7–10], notwithstanding most data suggest that diet-
ary intakes of key bone nutrients such as calcium,
vitamin D and proteins contribute to bone health
and reduce the risk of Fx later in life [2, 11]. Dietary
sources of nutrients are the preferred option and
pharmacological supplementation should only be targeted
to those individuals who do not get sufficient calcium
from their diet and who are at increased risk for OP [2].
Recent European consensus recommend adequate vitamin
D intake of 800 IU/day as well as calcium intake of
1000 mg/day [7, 12]. Until now, few studies targeted the
cost-effectiveness of calcium and vitamin D supplementa-
tion in OP [13, 14] and even less [15] assessed the public
health and economic impact of fortified dairy products
given to the general elderly population.
Methods
We designed a population-based model to forecast and
compare the potential population health outcomes and
medical costs following an appropriate daily intake of
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calcium/vitamin D in Belgium. Appropriate daily intake
was obtained by the administration, on top of the regu-
lar diet, of a daily dairy supplementation containing
1000 mg of calcium and 800 IU of vitamin D [7, 12].
This amount can be achieved with 1 l of milk (35 g
of proteins), 100 g of Comte cheese (28 g proteins)
or 4 yogurts (20 g of proteins). The model was actu-
ally an extension of an extensively published and vali-
dated cost-effectiveness microsimulation model of OP
management [13, 16–18]. The model was reengineered to
accommodate multiple age cohorts, constituent of a popu-
lation [19].
We used the median variant population projection
2014–2060 from the SPF Economie, the official source
for socio-demographic data in Belgium [20, 21]. Projec-
tions for 4 female and 4 male cohorts aged 50, 60, 70
and 80 years on the 1st of January 2015 were extracted
(birth cohorts 1965, 1955, 1945 and 1935).
The 8 cohorts were stratified according to their base-
line risk of OP Fx: general population, population with
osteoporosis (as defined by a BMD T-score ≤ 2.5) and
population with a prevalent vertebral or hip Fx. Baseline
prevalence estimates per age were derived from litera-
ture [3]. Prevalence assumptions and resulting numbers
of individuals with OP and a prevalent hip or vertebral
Fx in age strata are presented in Tables 1 and 2.
In the model, the occurrence of Fx at individual ages
is modelled through a health-state transition process
(Markov model). Individuals begin either in the general
population within the non-Fx state, in the OP popula-
tion within the non-Fx state or in the OP population
within the prevalent Fx state. Individuals then progress
according to their baseline characteristics and age-
specific Fx risk through the non-Fx stage, hip Fx stage,
vertebral Fx stage, wrist Fx stage or other Fx stage.
As it is a population-based model, the size of each co-
hort corresponds to the actual size of the corresponding
age cohort in the Belgian population. Hence, the adapted
model differs from the previous microsimulation model
on the target population dynamics as it does not assume
a hypothetical and microsimulated cohort of patients
but projects the impact of calcium/vitamin D supple-
mentation, through dairy products, on a specific age co-
hort over its respective remaining lifetime. All transition
probabilities were recalculated as annual transition prob-
abilities as the original microsimulation model uses 6-
month probabilities.
Each year, all individuals can die from age-specific
background mortality from any health state.
As for the population size estimates above, the age-
specific background mortality rates were taken from the
SPF Economie [20, 21]. We assumed that hip Fx in-
creased death probabilities by 5.5, as evidenced in a
meta-analysis [22]. The same excess mortality was as-
sumed for vertebral Fx but not for wrist and others Fx.
The risk of hip Fx was derived from the Belgian na-
tional database of hospital bills [23]. Since the incidence
of non-hip Fx was not known, we applied the age-
specific ratio of index Fx to hip Fx in Belgium as found
in Sweden [24]. All estimates were interpolated using ex-
ponential regression to obtain age-specific risk of Fx.
We assumed an increased risk of Fx for individuals who
had a prior Fx at the same location. These increased
relative risks were 2.3, 4.4, 3.3 and 1.9 for hip, vertebral,
wrist and others Fx, respectively [16, 25, 26].
Calcium/vitamin D supplementation effectiveness in
the reduction of Fx incidence was taken from a
recent study [13] that reviewed and synthesized meta-
analyses previously published on the subject. Cal-
cium/vitamin D supplementation has been shown to
reduce the risk of hip Fx by 18 % (RR = 0.82 95 %
CI:[7.1–0.94] in a meta-analysis of 6 trials including
45.509 patients) [27], the risk of vertebral Fx by 13 %
(RR = 0.87 95 % Cl:[0.75–1.01] in a meta-analysis in-
cluding 45.164 patients) [28] and the risk of non-hip
non-vertebral Fx by 20 % (RR = 0.80 95 % Cl:[0.72–
0.89] in a meta-analysis of 9 trials including 32.285
patients) [29]. Patients were assumed to follow cal-
cium/vitamin D supplementation for their remaining
lifetime. The protective effect of calcium/vitamin D
supplementation on Fx risk was thus assumed to remain
constant over time.
Table 1 Prevalence of osteoporosis and vertebral/hip fracture in
4 birth cohorts of women
Age Totala General Osteoporosisb Prevalent fracturec
% N % N % N
50 83,691 93.3 % 78,084 6.6 % 5524 0.1 % 84
60 70,979 81.9 % 58,132 16.3 % 11,570 1.8 % 1278
70 52,754 67.0 % 35,345 28.6 % 15,08 84.4 % 2321
80 41,157 40.1 % 16,504 47.2 % 19,426 12.7 % 5,2271
aSPF Economie. Ref. 20–21
bBMD T-Score ≤ 2.5. Ref. 22
cPrevalent hip or vertebral Fx. Ref 22
Table 2 Prevalence of osteoporosis and vertebral/hip fracture in
4 birth cohorts of men
Age Totala General Osteoporosisb Prevalent fracturec
% N % N % N
50 85,138 97.2 % 82,754 2.6 % 2214 0.2 % 170
60 69,040 91.9 % 63,448 6.7 % 4626 1.4 % 967
70 47,455 88.5 % 41,998 8.5 % 4034 3.0 % 1424
80 29,235 57.0 % 16,664 36.0 % 10,525 7.0 % 2046
aSPF Economie. Ref. 20–21
bBMD T-Score ≤ 2.5. Ref. 22
cPrevalent hip or vertebral Fx. Ref 22
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The perspective for the cost calculation is that of the
Belgian health care payers (government and patients) as
recommended in the Belgian pharmacoeconomics guide-
line [30]. Only direct medical costs were taken into
account. The hospitalization cost of hip Fx was retrieved
from the Belgian national database of hospital bills for
the year 2007 [13, 17, 18]. Extra costs in the year follow-
ing a hip Fx were derived from a prospective study of
159 women [31]. The costs of non-hip Fx were esti-
mated relative to hip Fx [32]. We assumed that non-hip
Fx were not associated with long-term costs. As for the
risks of Fx, all cost estimates were interpolated using
power or polynomial regression to obtain age-specific
cost of Fx. In the absence of official pricing data, as
opposed to pharmaceutical for instance, the price of the
supplementation with dairy products was derived from
the observed market price of vitamin D-enriched milk
and yogurt and was assumed at €250 per year and tested
between €150 and €350. All costs were expressed in
€2014 using the national health price index [20, 21] and
were discounted at 3 % per annum.
The model has a lifetime horizon for each age cohort
considered.
We projected the number of Fx avoided and life-years
gained (LYG) for each age cohort, from 50 to 80 years of
age in 2015 (born between 1935 and 1965). We also
computed the cost-per-Fx avoided and the cost-per-LYG
for each age cohort.
Results
Tables 3 and 4 summarize the projected health and cost
impacts of the recommended dairy daily intake versus
the absence of appropriate intake for women and men
aged 50, 60, 70 and 80 years in 2015 in Belgium. In total,
30,376 Fx would be avoided and 6605 LY would be
gained in the 4 age cohorts of women over their
remaining lifetime. In men, the number of Fx avoided
and LYG amounted 16,105 and 6144, respectively. The
greatest absolute gains were seen in the general popula-
tion segment, regardless of gender of baseline age.
The cost-per-Fx avoided was below €60,000 in women
(maximum of €55,524 in the general population aged
50 years with a cost of supplementation at €350 per
year) and below €90,000 in men (maximum of €86,463
in the general population aged 50 years with a cost of
supplementation at €350 per year). In both gender, the
cost-per-Fx avoided declined markedly with age and
baseline risk of Fx.
The cost-per-LYG (cost-effectiveness) was above
€100,000 in the 50 years age cohort for both women
and men, except in the prevalent Fx risk-group. The
cost-per-LYG declined along aging cohorts and in
the older cohort (80 years), the cost-per-LYG generally fell
below €50,000. In all instances, the cost-per-LYG tended
to be more favorable (i.e. lower) in older and riskier
cohorts.
Detailed results for each specific age cohort of women
and men are presented as Additional file 1.
Discussion
Our study suggest that by ensuring an adequate reple-
tion in calcium and vitamin D to the general population,
by the administration of dairy products providing
800 IU of vitamin D and 1000 mg of calcium daily, it is
possible to reduce the number of OP-related FX and to
provide a substantial number of LYG, in people for both
genders, currently aged from 50 to 80 years old. Our re-
sults also suggest that this intervention is cost/effective
in both genders, above the age of 70 years in the general
population and from 60 years and above in subjects at
increased risk of OP. Although, the clinical efficacy of
pharmacological or non-pharmacological interventions
may be consistent across settings, their impact on public
health or their economic value may differ, owing to
differences in epidemiologic variations, interventions-
related costs and effectiveness of available alternative
strategies [33, 34]. In Europe, OP accounts for more dis-
ability and LY lost than all other major musculoskeletal
conditions, except osteoarthritis but including rheuma-
toid arthritis [2]. With regards to neoplastic diseases, the
burden of OP is greater than all sites of cancer with the
exception of lung cancer [35]. Several studies assessed
the efficacy and efficiency of pharmacological interven-
tions in OP [36]. However, nutritional interventions
whereas considered as first-line measures in most guide-
lines dedicated to the management of OP [1, 2, 7, 12]
are less frequently studied in terms of their impact on
public health or health resources utilization [15]. This
study is the first to apply a validated cost-effectiveness
microsimulation model [16], adapted to a public health
perspective [19] to the outcomes of calcium and vitamin
D administration, as dairy products, on reduction of Fx
or on gain in LY and to determine whether such an
intervention may be considered cost-effective in the gen-
eral population and in individuals at increased risk of
OP-related Fx. The scarcity of available resources and
the increasing demand for healthcare require more ra-
tional assignment of resources and better definition of
priorities. In this scenario, economic evaluations provide
valuable information and LYG is widely recognized as an
appropriate outcome [37]. Our results show that vitamin
D-enriched dairy products, given to the general popula-
tion, from the age of 50 years can spare more than
30,000 OP Fx in women and more than 15,000 OP Fx in
men and save more than 6600 LY in women and more
than 6100 LY in men. As expected, the cost-effectiveness
of dairy product administration in OP, as it is the case
for any intervention, is strongly influenced by the cost of
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Table 4 Health and cost impact of recommended CA/Vit D dietary intake in men
Fracture avoided LYG
50y 60y 70y 80y 50y 60y 70y 80y
General 6383 4315 2351 675 1727 1540 1216 571
Osteoporosisa 279 498 342 601 49 131 149 479
Prevalent fractureb 40 195 223 203 6 41 80 155
Cost per fracture avoided Cost per LYG
50y 60y 70y 80y 50y 60y 70y 80y
General
Ca/Vit.D €150/year € 35,684 € 31,117 € 24,794 € 16,389 € 131,903 € 87,190 € 47,950 € 19,377
Ca/Vit.D €250/year € 61,073 € 54,030 € 44,275 € 31,334 € 225,753 € 151,392 € 85,627 € 37,048
Ca/Vit.D €350/year € 86,463 € 76,943 € 63,757 € 46,279 € 319,603 € 215,595 € 123,304 € 54,719
Osteoporosisa
Ca/Vit.D €150/year € 20,250 € 17,654 € 13,935 € 8873 € 115,310 € 66,932 € 32,000 € 11,124
Ca/Vit.D €250/year € 35,749 € 32,068 € 26,716 € 19,327 € 203,563 € 121,582 € 61,349 € 24,231
Ca/Vit.D €350/year € 51,248 € 46,482 € 39,497 € 29,781 € 291,816 € 176,231 € 90,697 € 37,337
Prevalent fractureb
Ca/Vit.D €150/year € 9214 € 7204 € 4546 € 1148 € 62,625 € 34,065 € 12,649 € 1505
Ca/Vit.D €250/year € 17,483 € 14,815 € 11,293 € 6799 € 118,823 € 70,057 € 31,423 € 8916
Ca/Vit.D €350/year € 25,751 € 22,427 € 18,040 € 12,451 € 175,022 € 106,049 € 50,197 € 16,327
aBMD T-score ≤ 2.5
bHip or vertebral
Table 3 Health and cost impact of recommended CA/Vit D dietary intake in women
Fracture avoided LYG
50y 60y 70y 80y 50y 60y 70y 80y
General 9928 6739 3497 1219 1305 1242 1040 706
Osteoporosis1 1051 1967 2131 1944 86 240 472 991
Prevalent fracture2 29 406 594 871 2 38 97 386
Cost per fracture avoided Cost per LYG
50y 60y 70y 80y 50y 60y 70y 80y
General
Ca/Vit.D €150/year € 22,462 € 19,094 € 14,467 € 8064 € 170,818 € 103,630 € 48,663 € 13,924
Ca/Vit.D €250/year € 38,993 € 33,990 € 27,182 € 17,815 € 296,532 € 184,479 € 91,430 € 30,759
Ca/Vit.D €350/year € 55,524 € 48,887 € 39,896 € 27,566 € 422,245 € 265,329 € 134,197 € 47,594
Osteoporosisa
Ca/Vit.D €150/year € 13,617 € 11,144 € 7690 € 3057 € 165,846 € 91,326 € 34,719 € 5997
Ca/Vit.D €250/year € 24,655 € 21,277 € 16,547 € 10,149 € 300,277 € 174,359 € 74,707 € 19,910
Ca/Vit.D €350/year € 35,692 € 31,409 € 25,404 € 17,240 € 434,709 € 257,392 € 114,696 € 33,822
Prevalent fractureb
Ca/Vit.D €150/year € 5941 € 3711 € 1049 € 0 € 83,603 € 39,497 € 6392 € 0
Ca/Vit.D €250/year € 11,988 € 9090 € 5856 € 1492 € 168,701 € 96,744 € 35,687 € 3369
Ca/Vit.D €350/year € 18,035 € 14,469 € 10,663 € 5532 € 253,799 € 153,992 € 64,982 € 12,493
aBMD T-score ≤ 2.5
bHip or vertebral
Ethgen et al. Archives of Public Health  (2015) 73:48 Page 4 of 7
the intervention and by the risk profile of the subject.
No standard for upper threshold of cost per LYG, that
would constitute an absolute value of the critical cost-
effectiveness ratio, is explicitly fixed [38]. However,
tentative guidelines place it in the range of $20,000 to
$100,000 per LYG [39], while other authors consider
that up to $166,000 per LYG, cost-efficiency is debat-
able [40].
The World Health Organization (WHO) suggests that
interventions with a cost-effectiveness ratio between 1
and 3-fold de Gross Domestic Product (GDP) per capita
of the country where the study is conducted are cost/
effective [41]. In Belgium, GDP per capita accounted
€37,857.75 in 2014. These figures, based on the WHO rec-
ommendations [41] suggest that cost-effective ratios below
€120,000/LYG are acceptable.
The cost-effectiveness ratio of our intervention re-
mains below or around €100,000/LYG in the general
population at 70 years and above, while these values are
observed from 60 years on, in subjects at increased risk
of OP Fx except in the sensitivity analysis setting up the
price of the dairy intervention at €350/year.
Like any health economic study, our work is based on
a number of assumptions. The cost-effectiveness is crit-
ically dependent on the evidence for efficacy of the inter-
vention. It could be argued that prospective, randomized
controlled studies establishing the anti Fx efficacy of
dairy product are currently missing [42]. Some cohort
studies also generated unconclusive evidence on reduction
of Fx following milk intake. However, these cohorts did
not use any vitamin D-enriched dairy products [43–46],
while our analysis is based on the intake of dairy products
providing the amount of calcium and vitamin D, which
are considered by most experts and recommendations
from scientific organizations as appropriate to improve
bone health [1, 2, 7, 12]. Divergent opinion, challenging
the interest of calcium and vitamin D in OP [47] or
reporting putative increase in adverse effects following cal-
cium supplementation [48] appear to be insufficiently sub-
stantiated [49] and, at any rate more directed towards
calcium pharmacological supplementation than against
dairy products intake [48].
Our extrapolation of the anti-Fx efficacy obtained with
pharmacological supplementation of calcium and vita-
min D to dairy products providing the same amount of
nutrients is indeed likely to be highly conservative.
Several studies have documented the link between low
intake of dairy foods and decreased bone mineral density
or increased Fx risk [50, 51].
At every stage of life, adequate dietary intake of key
bone nutrients including not only calcium and vitamin D
but also proteins contributes to muscle and bone health,
thereby reducing the risk of falls, OP and Fx later in life
[12]. Dairy products are rich in proteins [52]. There is no
clear-cut evidence that individuals aged more than 50 years
old have a deficit in protein intake similar to what is re-
ported for calcium and vitamin D [53]. However, it is pos-
sible that our analysis, based only on the beneficial effects
of calcium and vitamin D on bone, without modelling the
potential benefits of proteins underestimates the positive
outcomes of dairy products intake.
Furthermore, it is well known that the efficacy of anti OP
medications, including pharmacological supplements of
calcium and vitamin D is decreased as a result of poor ad-
herence [54]. The impact of low compliance and persist-
ence on the cost-effectiveness of these treatments is well
documented [55]. Dairy food has been shown to be an ap-
propriate vehicle to provide calcium, with good compliance
compared to pharmacological supplements [15, 56], which
might have a positive effect on the effectiveness of our
approach. This might also be emphasized because the pu-
tative deleterious effect of pharmacological calcium supple-
mentation on myocardial infarction was never reported
following dairy products intake. Eventually, different stud-
ies showed that calcium and vitamin D supplementation
have other health benefits effects. So, studies suggested that
calcium and vitamin D may reduce the risk for breast can-
cer mainly in premenopausal women [57] and colon cancer
in older women [58]. A meta-analysis has also indicated
that vitamin D may have a small beneficial effect on cardio-
vascular risk and mortality [59].
All these potential benefits might increase the number
of LYG by our dairy product supplementation and,
subsequently, improve the cost/effectiveness of the inter-
vention by reducing the cost/LYG. Eventually, we only
assessed beneficial outcomes generated by the calcium/
vitamin D supplementation in terms of LYG. Improve-
ments in quality of life and subsequent quality-adjusted
LY were also reported following the Fx risk reduction in-
duced by a dietary supplementation in calcium/vitamin
D and reflect a qualitative benefit that is superimposed
to the quantitative outcome assessed by the LYG.
Conclusion
Dietary sources of nutrients are recommended as appro-
priate to ensure adequate calcium and vitamin D reple-
tion. This recommendation, widely claimed to be justified
in terms of efficacy is also supported by our public health
impact and health economics analyses.
Additional file
Additional file 1: Results in women and men. (PDF 212 kb)
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